agency chose a class-wide approach rather than singling out one medication.
The FDA did not make this decision based on a single study or anecdotal reports. The agency’s review began after a retrospective cohort study published in JAMA Ophthalmology in 2024 suggested an association between semaglutide and NAION. In that study, which focused on patients seen by neuro-ophthalmologists at a single academic center, investigators reported a higher risk of NAION among patients using semaglutide compared with those taking non-GLP-1 RA medications. The increased risk was reported both in individuals with